Abstract
Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial
Journal of clinical oncology, Vol.35(4_suppl), pp.348-348
02/01/2017
DOI: 10.1200/JCO.2017.35.4_suppl.348
Abstract
348
Background: Neuroendocrine tumor progression is associated with decline in quality of life, both due to tumor and hormone-related symptoms. The Phase III NETTER-1 trial randomized patients with advanced, progressive midgut NETs to receive treatment with
177
Lu-DOTATATE (
177
Lu; Lutathera) versus high-dose (60 mg) Octreotide LAR (Oct). EORTC questionnaires C30 and GINET21 were assessed during the trial in order to determine the impact of treatment on health-related quality of life (HRQoL). Methods: Patients completed EORTC QLQ-30 and QLQ-G.I.NET21 questionnaires at baseline and every 12 weeks thereafter until disease progression. Raw scores were converted to a 100-point scale and individual changes from baseline scores were assessed. Clinically relevant ( ≥ 10 point) deterioration/improvement was considered clinically significant. Results: Clinically and statistically significant improvements in QoL were observed in the
177
Lu arm versus the Oct arm at certain time points in key domains of HRQoL including global health status and diarrhea. In mean, global health status improved in 28% of patients on
177
Lu arm vs. 15% on Oct, and worsened in 18% of patients on
177
Lu vs. 26% on Oct. Diarrhea improved in 39% of patients on
177
Lu vs. 23% on Oct, and worsened in 19% of patients on
177
Lu vs. 23% on Oct. There was a trend towards improvement in pain that was not statistically significant. Flushing appeared to improve compared to baseline in both arms of the study with no clear advantage to treatment with
177
Lu vs. Oct. Conclusions: QoL analysis suggests benefit in important domains associated with
177
Lu treatment compared to high-dose octreotide in patients with advanced midgut NETs, and confirms the treatment value of
177
Lu on patient QoL, in addition to the meaningful increase in progression-free survival already reported. Clinical trial information: NCT01578239.
Details
- Title: Subtitle
- Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial
- Creators
- Jonathan R. Strosberg - Moffitt Cancer CenterEdward M. Wolin - University of KentuckyBeth Chasen - The University of Texas MD Anderson Cancer CenterMatthew H. Kulke - Dana-Farber Cancer InstituteDavid L Bushnell - United States Department of Veterans AffairsMartyn E. Caplin - The Royal Free HospitalRichard P. Baum - Zentralklinik Bad BerkaPamela L. Kunz - Stanford UniversityTimothy J. Hobday - Department of Oncology, Mayo Clinic College of Medicine, Rochester, MNAndrew Eugene Hendifar - Cedars-Sinai Medical CenterKjell E. Oberg - Uppsala University HospitalMaribel Lopera Sierra - Advanced Accelerator Applications, New York, NYDik J. Kwekkeboom - Erasmus MCPhilippe B. Ruszniewski - Beaujon HospitalEric Krenning - Erasmus MC
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.35(4_suppl), pp.348-348
- DOI
- 10.1200/JCO.2017.35.4_suppl.348
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 02/01/2017
- Academic Unit
- Radiology
- Record Identifier
- 9984320099802771
Metrics
8 Record Views